Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
When I was young, I decided to go to medical school. At the entrance exam, we were asked to rearrange the letters
P N E I S
and form the name of an important body part which is most useful when erect.
Those who answered SPINE are doctors today, while the rest are on tik tok.
MGCLF
Wonder what's going on today, trading went from average 119k to 10.1M.
MGC Pharma attracts $5m grant for its Malta-based production facility.
https://stockhead.com.au/health/mgc-pharma-attracts-5m-grant-for-its-malta-based-production-facility/
MGC Pharmaceuticals confirms Phase II trial success for anti-inflammatory COVID treatment
https://stockhead.com.au/health/mgc-pharmaceuticals-confirms-phase-ii-trial-success-for-anti-inflammatory-covid-treatment/
Nancy Pelosi’s Husband Bought Stock Options in Apple, Tesla, and Disney.
https://www.barrons.com/articles/nancy-pelosi-husband-bought-apple-tesla-disney-stock-options-51611496598
https://seekingalpha.com/article/4400645-microsoft-apple?utm_medium=email&utm_source=seeking_alpha#alt1&mail_subject=msft-microsoft-or-apple-the-showdown&utm_campaign=rta-stock-article&utm_content=link-2
There is an added element that should be weighed when considering Mac/iPad revenues. The development of the M1 chip, which will be used in the Macintosh line of computers, is estimated to cost $40 to $50 per unit versus $200 spent on the Core i5 processor it replaced. If those figures are correct, Apple would harvest $2.5 billion in savings over the next fiscal year. There are reasons to believe the actual costs for the transition to the M1 from the i5 will be double the quoted figure. Nonetheless, the savings would still be substantial.
https://clinicaltrials.gov/ct2/show/NCT04382040?term=ArtemiC&draw=2&rank=1
Wow, Frankincense.
ArtemiC is a medical spray comprised of Artemisinin (6 mg/ml), Curcumin (20 mg/ml), Frankincense (=Boswellia) (15 mg/ml) and vitamin C (60 mg/ml) in micellar formulation for spray administration.
Fantastic, I was so focused on Laredo, I forgot about SORC. So basically the group is Laredo Oil, Stranded Oil, Natrona, Caddo and Cat Creek (50% interest).
Natrona County Holdings LLC, here are some related links,
https://www.dnb.com/business-directory/company-profiles.natrona_county_holdings_llc.7427878e4876c568f640804b1b2069cd.html
http://www.drillingedge.com/wyoming/operators/natrona-county-holdings-llc/2510
https://www.shaleexperts.com/company/Natrona-County-Holdings-LLC#
https://www.shalexp.com/natrona-county-holdings-llc
https://www.manta.com/c/mh0h352/natrona-county-holdings-llc
Caddo Parish Holdings LLC, here are some related links -
http://www.drillingedge.com/louisiana/operators/caddo-parish-holdings-llc/c426
http://www.drillingedge.com/louisiana/operators/caddo-parish-holdings-llc/c426
https://www.manta.com/c/mh0h352/natrona-county-holdings-llc
https://thedrillings.com/owners/2357306
What we need now is to consistently be trading over 500,000 per day. Price follows volume.
Why I'm invested in Laredo Oil. My comments are in italics, and the text is from the last 10Q.
As consideration for the SORC Shares, Buyer paid to Alleghany $55,000 and the Company agreed to pay to Alleghany a revenue royalty of 5.0% of the Company’s future revenues and net profits relating to oil, gas, gas liquids and all other hydrocarbons, subject to certain adjustments, for a period of seven years after the closing.
So with the ability to freely utilize UGD 3.0 technology, they have to pay a minute royalty of 5%.
Further, pursuant to the SORC Purchase Agreement, Laredo and Alleghany entered into a Consulting Agreement dated as of December 31, 2020 (the “Consulting Agreement”), pursuant to which Seller agreed to pay an aggregate of approximately $1.245 million during calendar year 2021 in consideration of Laredo causing certain individuals, including Mark See, Laredo’s Chief Executive Officer and Chairman, and Chris Lindsey, Laredo’s General Counsel and Secretary, to provide consulting services to Alleghany (for a period of three years for Mr. See and one year for Mr. Lindsey).
They will still have consulting revenue from Alleghany.
In connection with the SORC Purchase Transaction, the notes were amended, restated and consolidated into one note including all accrued interest through December 31, 2020, the date of the transaction, for a total of $631,434 (the “Senior Consolidated Note”) with a maturity date of June 30, 2022. The Senior Consolidated Note requires any stock issuances for cash be utilized to pay down the outstanding loan balance unless written consent is obtained from Alleghany. As part of the SORC Purchase Transaction, the Company agreed to secure repayment of the Senior Consolidated Note with certain equipment owned by SORC Holding and to reduce the note balance with any proceeds received from any sales of such equipment. The note bears no interest until January 1, 2022 whereupon the interest rate increases to 5% per annum through maturity. Principal with all accrued and unpaid interest is due at maturity.
A 1 year interest free loan, and then 5% for 6 months next year when it becomes due on June 30.
The Company plans to use its cash and cash equivalents on hand, and the proceeds from the Consulting Agreement, to maintain the mineral rights acquisition program in Montana and to pay its operating costs.
Planning future expansion.
No warrants were issued during the first two quarters of fiscal years 2021 or 2020. As of November 30, 2020, there were 5,374,501 warrants remaining to be exercised at a price of $0.70 per share to Sunrise Securities Corporation to satisfy the finders’ fee obligation associated with the Alleghany transaction. The warrants will expire June 14, 2021 and are currently exercisable.
http://www.sunrisecorp.com/#:~:text=Sunrise%20Securities*%20("Sunrise",80%20domestic%20and%20international%20companies.
So instead of paying the fees associated with the Alleghany deal, they issued warrants to an Investment bank, which will expire in 5 months. So on June 14, 2021 if the Bank wants in on the action, they have to pony up $3,762,150.70
The Outstanding number of shares is 54,514,765, and has been that amount for the past 3 years. The float is 19,493,232.
But what is even more impressive to me, as a former banker,
The balance sheet is DEVOID OF GOODWILL.
The balance sheet is DEVOID OF INTANGIBLES.
Got another 100k LRDC today @ $0.064. Will post what I like about the stock in a couple of days, spent the whole long weekend digging into them.
Wish SELB would revisit its glory days.
Reminds me of AMRN, which was setback by a single question at their ADCOM meeting. Will be carrying those wounds for many years to come, unless LL provides a $$ transfusion.
I was simply reporting an observation. The good news is, it has since been changed to $4.73
You may be disappointed, since it will be for November 30, while all the action took place at year end.
So yesterday, CYDY trading closed at $4.93 and the after 4 Forms T were at $5.00, and TDA chose to use $4.93 as the closing price.
Today CYDY trading closed at $4.73 and the after 4 Forms T were at $4.63, and TDA chose to use $4.63 as the closing price.
What's up with that ?
Speaking of Rolodexs, here is a word that seems to be missing from yours - Overseas. Said word, Overseas in turn has a Rolodex of its own, with words like Switzerland, Belgium, Germany, France, and another 100 plus more. I'm sure one of them would be happy to sell Vyrologix to the world, without a care about BP.
I am wondering what's wrong with a mechanical engineer ? Lots of recent posts here about Gilead, founded in 1987. Donald Rumsfeld became a director in 1988, and was later Chairman from 1997 to 2001. What medical school did he attend ??
Can't see what ACST has going for it, ca-pre failed. Need a double here to break even.
How does PTE look to you ?
Tech did not do well today, AAPL -$4.41, MSFT -$5.65, ORCL -$0.15, ADBE ouch -$19.38 meanwhile DJI +$437.80
There is also Inventia and PTE.
Apple Wins a Patent for an Interactive Laser Projection System for Presentations, a Virtual Desktop & more.
https://www.patentlyapple.com/patently-apple/2020/12/apple-wins-a-patent-for-an-interactive-laser-projection-system-for-presentations-a-virtual-desktop-more.html
As I shared the following recently with you -
Oh, I love AAPL. It provided me with my first $ignificant Milestone, and is about to do a repeat performance, so I am as they say, a "fan boy".
Talk about iCar can only help my portfolio even more.
And this with someone else -
I did not keep up with portfolio concentration, so AAPL is now 87% of my portfolio. The way I see it, is that with that much concentration, if there is a market correction of up to 40%, it won't affect me tremendously. My Avg. cost is 20.98, so I am up 545%, having started buying in Jan.2010.
Of course, with that much of a concentration, I do not have much left over for diversification.
My last trade was Nov.18, bought on MARGIN 3,000 @ $118.98 = $356,210. On 12/24, sold 2,750K @ $132.55 = $364,520 So I came out with +250 shares, and $8,310.00 before cost of margin, say $1,524.00 (356210 x 40 days @ 3.85%)
Looking forward to rinse and repeat, but will probably add other tech, next year.
Tried this in 2019, but HAL got the better of me.
Looking to add 5K ORCL tomorrow, hopefully under $65.00 then probably sell the $66 Jan15 options to cover margin, and collect my $1,200.00 divvy on the way out.
Happy new year to all, and a bright and covid free 2021.
Neat trick, posting this on 12/24 while I see it in today's issue of WSJ 12/26&27.
B-O, that is the front end, you short 2000 at $5 and have to cover at $10. But you don't have the cash ($10K) from the sale (folks don't usually have proceeds sitting in their account), and now you have to find $20K, so the broker sells other stock you own, and if they have gains in those stocks, then they have a tax situation, if it happens in the next 4 days. Hope that happens.
I have seen shorts escape before, laughing all the way to the bank. As of 12/15, short interest was 27,043,506 which I suspect has risen, since we closed that day @ $3.46, and subsequently went up to $7.00 so during the next 7 trading days, my guess is we hit 28M short. It would be interesting to see what would happen if we were all to place a sell order for 10 shares @ $20.00 for Monday.
He gets it, the Batteries.
https://seekingalpha.com/article/4396067-quick-perspective-on-apple-car
Merry Christmas.
Some light in the tunnel. Merry Christmas to all.
FDA Provides Guidance for Adding an Open-Label Extension to CytoDyn’s Phase 3 Trial for Severe-to-Critical COVID-19 Patients Until Trial Data is Unblinded
Download as PDFDecember 24, 2020 7:46pm EST
The agency will also consider eINDs for patients in other hospitals who qualify for inclusion criteria similar to CD12
The CD12 trial completed enrollment with 394 patients on December 16
VANCOUVER, Washington, Dec. 24, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company", a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the U.S. Food and Drug Administration (“FDA”) provided guidance to the Company to add an open-label extension to its Phase 3 trial (“CD12”) and specific criteria for the continuation of eINDs for patients meeting the inclusion/exclusion criteria of CD12.
The CD12 protocol will be amended for adding the open-label arm extension and submitted to the FDA on Monday, December 28, 2020. Upon clearance, each CD12 participating clinical trial site will have the option of enrolling additional qualified patients, with all patients receiving leronlimab. Treatment of qualified patients will continue until the trial’s data is unblinded.
The FDA also provided specific guidance for the benefit of physicians seeking an eIND for COVID-19 patients, which must first meet the inclusion/exclusion criteria of the CD12 study, and such criteria will be provided to them in the form of a checklist.
Mahboob Rahman, M.D., Ph.D., Chief Scientific Officer and Head of Clinical Development for CytoDyn, stated, “We are pleased that at a time when COVID-19 cases and mortality continue to increase, the FDA’s thoughtful advice will allow a specified subset of patients access to leronlimab, while we await the results of the randomized placebo-controlled portion of the Phase 3 study. We are committed to work with the FDA and the health care providers to improve the outcomes of COVID patients.”
Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented, “We are very thankful to the FDA for providing guidance on accessing our drug pending the results of CD12, especially during these unprecedented times. CytoDyn will provide the precise requirements for potential participation in the new CD12 open-label extension and physicians seeking eINDs, while we eagerly await the unblinding of the data. The results of our CD10 trial will not support an eIND request.”
Remember the market closes at 1:00 p.m. EST tomorrow. Recall GM and Ford a few years ago. Car manufacturing is too fraught with problems. No, battery technology is where the $$ are. For the month so far I have bought 2 x 32 of AAA and 2 x 40 of AA. Next time you buy a Duracell battery, remember you are rewarding Warren Buffet's Berkshire Hathaway.
Make a car, no, but they may partner up to supply the electronics - I'll take 2.
Even in after hours today, doubt it will get to $132.00
We need to find out can the FDA be held accountable in a court of law.
AMRN took the FDA to court TWICE and won both times.
In case I don't read this board for a few days, here's wishing you all stay safe, and have a reverent Christmas. May you not have any tax loss selling, and may the force be with you i.e. the January effect.
I still don't get the heavy reliance on RLF. All NeuroRX is getting from that is a slice of the Aviptadil profits, but it seems that some folks are including RLF in the BRPA deal ???
Ain't that something, on the day TSLA enters the S&P 500, amidst fears that folks were selling AAPL to buy TSLA, somehow news about the iCar comes out. I smell a leak. Oh Tim you're making Steve really proud of you. Tomorrow is going to be a fun day with AAPL, already hit $132 after hours, hope it bounces more.
This is so funny. Rumor was that folks were going to sell AAPL to buy TSLA, since TSLA was going to be included in the S&P 500 today, 12/21. BUT somehow, the news of the iCar gets rolled out today, TSLA drops, AAPL rises. Elon Musk needs to realize that Tim Cook is a corporate descendant of Steve Jobs.